Results 1 to 10 of about 187,919 (323)

Long-term benefit of vasodilating beta-blockers in acute myocardial infarction patients with mildly reduced left ventricular ejection fraction. [PDF]

PLoS ONE
Beta-blockers have been considered the cornerstone of treatment for patients with acute myocardial infarction (AMI). However, long-term benefits of vasodilating beta-blockers remain uncertain.
Ki Yung Boo, Miyeon Kim, Jae-Geun Lee, Geum Ko, Joon Hyouk Choi, Song-Yi Kim, Seung-Jae Joo, Jin-Yong Hwang, Seung-Ho Hur, Kwang Soo Cha, Myung Ho Jeong, KAMIR-NIH registry investigators   +11 more
doaj   +2 more sources

Impact of in-hospital oral beta-blockers initiation on long-term outcomes in ST-elevation myocardial infarction patients with cardiogenic shock [PDF]

Frontiers in Medicine
BackgroundEarly revascularization enables ST-elevation myocardial infarction (STEMI) patients with cardiogenic shock (CS) to initiate oral beta-blockers once hemodynamic stability is achieved, but the impact of such initiation on prognosis remains ...
Xiaojin Gao, Mengyuan Liu, Jing Xu, Ling Li, Min Chen, Xinyue Lang, Shaobin Jia, Bin Ning, Haiyan Xu, Lei Song, Yuan Wu, Jun Zhang, Fenghuan Hu, Shubin Qiao, Yongjian Wu, Yanyan Zhao, Yang Wang, Wei Li, Chen Jin, Jingang Yang, Yuejin Yang   +20 more
doaj   +2 more sources

Long-Term Effect of Non-Selective Beta-Blockers in Patients With Rheumatoid Arthritis After Myocardial Infarction—A Nationwide Cohort Study

Frontiers in Pharmacology, 2021
Objectives: Rheumatoid arthritis (RA) is an independent nontraditional risk factor for incidence of myocardial infarction (MI) and post-MI outcome is impaired in the RA population.
Sheng-Fu Liu, Sheng-Fu Liu, Sheng-Fu Liu, Chih-Kuo Lee, Chih-Kuo Lee, Chih-Kuo Lee, Kuan-Chih Huang, Kuan-Chih Huang, Lian-Yu Lin, Lian-Yu Lin, Mu-Yang Hsieh, Mu-Yang Hsieh, Mu-Yang Hsieh, Ting-Tse Lin, Ting-Tse Lin   +14 more
doaj   +1 more source

Neuropsychiatric Consequences of Lipophilic Beta-Blockers

Medicina, 2021
Beta-blockers are a class of drugs with important benefits in cardiovascular pathology. In this paper, we aim to highlight their adverse and therapeutic effects in the neuropsychiatric field.
Sabina Alexandra Cojocariu, Alexandra Maștaleru, Radu Andy Sascău, Cristian Stătescu, Florin Mitu, Maria Magdalena Leon-Constantin   +5 more
doaj   +1 more source

Beta-blockers for hypertension [PDF]

Cochrane Database of Systematic Reviews, 2017
Beta-blockers refer to a mixed group of drugs with diverse pharmacodynamic and pharmacokinetic properties. They have shown long-term beneficial effects on mortality and cardiovascular disease (CVD) when used in people with heart failure or acute myocardial infarction. Beta-blockers were thought to have similar beneficial effects when used as first-line
Wiysonge, Charles S., Bradley, H. A., Volmink, J., Mayosi, B. M., Opie, L. H.   +4 more
openaire   +3 more sources

The progress and controversial of the use of beta blockers in patients with heart failure with a preserved ejection fraction

International Journal of Cardiology: Heart & Vasculature, 2020
Beta blockers are a recommended therapy in patients with heart failure with reduced ejection fraction(HFrEF). Beta blockers markedly and unequivocally reduce mortality in patients with heart failure with reduced ejection fraction. However, the beneficial
Xizhen Xu, Dao Wen Wang
doaj   +1 more source

The use of beta-blockers before major trauma and posttrauma outcome: A nationwide population-based study

Journal of Medical Sciences, 2022
Background: Beta-blockers are widely used for the treatment of arrhythmia, hypertension, and congestive heart failure. Major trauma causes significant blood loss and subsequent tachycardia and hypotension.
Jen-Chun Wang, Wu-Chien Chien, Chi-Hsiang Chung, Po-Chuan Chen, Chin-Li Chen, Shih-Hung Tsai   +5 more
doaj   +1 more source

Association between Incidence of Prescriptions for Alzheimer’s Disease and Beta-Adrenoceptor Antagonists: A Prescription Sequence Symmetry Analysis

Pharmaceuticals, 2023
Background: Alzheimer’s disease (AD) is the most common cause of dementia, with a growing number of patients worldwide. The association between AD and treatment with drugs targeting the beta-adrenergic receptor is controversial.
Ali Alghamdi, Maarten J. Bijlsma, Stijn de Vos, Catharina C.M. Schuiling-Veninga, Jens H. J. Bos, Eelko Hak   +5 more
doaj   +1 more source

The EuroHeart Failure Survey programme—a survey on the quality of care among patients with heart failure in Europe Part 2: treatment [PDF]

, 2003
National surveys suggest that treatment of heart failure in daily practice differs from guidelines and is characterized by underuse of recommended medications.
Aguilar, JC, Cleland, J, Cohen-Solal, A, Dietz, R, Eastaugh, J, Follath, F, Freemantle, N, Gavazzi, A, Hobbs, R, Komajda, M, Korewicki, J, Madeira, HC, Mason, J, Moiseyev, VS, Preda, I, Swedberg, K, Van Gilst, WH, Widimsky, J   +17 more
core   +5 more sources

Transsulfuration pathway thiols and methylated arginines: the hunter community study [PDF]

, 2013
Background: Serum homocysteine, when studied singly, has been reported to be positively associated both with the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine [ADMA, via inhibition of dimethylarginine dimethylaminohydrolase ...
Attia, John R., Carru, Ciriaco, Mangoni, Arduino A., McEvoy, Mark, Zinellu, Angelo   +4 more
core   +6 more sources